Last reviewed · How we verify

NCT04563247

Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs

Completed Last updated 15 February 2022
What this trial tests

trial testing IgG SARS CoV 2 antibodies in Covid19 in 970 participants. Completed in 8 February 2021.

Timeline
1 July 2020
Primary endpoint
8 February 2021
8 February 2021

Quick facts

Lead sponsorLahore General Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment970
Start date1 July 2020
Primary completion8 February 2021
Estimated completion8 February 2021
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Lahore General Hospital

Who can join

Adults 20 to 60, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is about the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Lahore General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04563247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing